Research programme: histone deacetylase inhibitors - FORUM Pharmaceuticals

Drug Profile

Research programme: histone deacetylase inhibitors - FORUM Pharmaceuticals

Alternative Names: EVX 001688; HDAC inhibitors - EnVivo; HDACi - EnVivo; Isotope-selective HDAC inhibitors (Series B) - EnVivo

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator MethylGene
  • Developer CHDI; Mirati Therapeutics
  • Class Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Huntington's disease; Neurodegenerative disorders; Parkinson's disease

Most Recent Events

  • 02 Apr 2014 EnVivo Pharmaceuticals is now called FORUM Pharmaceuticals
  • 28 Jun 2013 Mirati Therapeutics is now the parent company of MethylGene
  • 25 Mar 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top